Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | -299K | -301K | -361K |
| Operating Income | -29M | -35M | -25M | -21M | -21M |
| EBITDA | -29M | -35M | -20M | -19M | -21M |
| Net Income | -29M | -32M | -21M | -19M | -21M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.9203
+0.03% today
1Y Change
+33.33%
Window
Jun 26, 2025 → Jun 18, 2026
Coverage: 246 bars · Jun 26, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Oncolytics Biotech Inc. (ONCY) is a Healthcare stock with a market cap of $120.00M and listed on NASDAQ. The stock last traded around $0.92 and up 33.3% across the available one-year price window (Jun 26, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +26.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +26.8%, free cash flow +26.1% with operating margin 0.0% and ROIC -1715.9%. Stock Foundry combines ONCY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ONCY
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ONCY Max Drawdown
-45.07%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ONCY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$21.0M
-10.0% YoY
Free Cash Flow
-$22.7M
+2.9% YoY
Revenue Growth
+0.0%
EPS Growth
+26.8%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | -299K | -301K | -361K |
| Operating Income | -29M | -35M | -25M | -21M | -21M |
| EBITDA | -29M | -35M | -20M | -19M | -21M |
| Net Income | -29M | -32M | -21M | -19M | -21M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5M | 16M | 35M | 12M | 41M |
| Total Assets | 8M | 20M | 39M | 37M | 46M |
| Total Liabilities | 11M | 14M | 11M | 11M | 10M |
| Shareholder Equity | -4M | 6M | 28M | 27M | 36M |
| Total Debt | 563K | 1M | 423K | 373K | 655K |
| Net Debt | -5M | -15M | -34M | -11M | -41M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
22M
+3.9% YoY
Capital Expenditures
286K
-419.9% YoY
Free Cash Flow
23M
+2.9% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-1292.7%
Debt / Equity
-0.15x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.